Evotec expands CRISPR-based technology offering with licence from ERS Genomics

03-May-2018 - Germany

Revolutionize your production: real-time Raman analysis for maximum efficiency

Efficient inline analysis for liquids and solids

User-friendly software for effortless Design of Experiments (DoE)

Evotec AG announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space.

The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “Obtaining this new licence from ERS Genomics is the latest example of Evotec’s investment in gene editing technologies. Together with our world-leading iPSC and phenotypic screening platforms, the continued expansion of CRISPR-based technologies at Evotec provides our partners with a unique solution for the identification of novel disease modifying genes.”

Eric Rhodes, CEO of ERS, commented: “We’re thrilled to add Evotec to our growing list of licensees of CRISPR-Cas9 technology. As one of the world’s leading providers of customised research solutions it’s very gratifying to see Evotec actively expanding its use of the technology across several key areas.”

https://www.bionity.com/en/news/1154850/evotec-expands-crispr-based-technology-offering-with-licence-from-ers-genomics.html